A new phase 2 clinical trial suggests that a chemotherapy-free, minimal residual disease (MRD)–driven treatment strategy may offer durable remissions and the possibility of time-limited therapy for ...
The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...
Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...
The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...
Eli Lilly receives US FDA expanded indication approval for Jaypirca to treat adults with relapsed or refractory chronic lymphocytic leukaemia: Indianapolis Saturday, December 6, 2 ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...
Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...
Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...
Eli Lilly and Company has received approval from the US FDA for the expanded use of Jaypirca tablets in 100mg and 50mg doses.
The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or ...
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...
VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback